Hogan Lovells Acted on Perspective’s $87.4 Million Financing for Targeted Cancer Therapy
Hogan Lovells, a global law firm, advised Perspective Therapeutics (“Perspective”) on its US$87.4 million private placement
Hogan Lovells Acted on Perspective’s $87.4 Million Financing for Targeted Cancer Therapy
Hogan Lovells, a global law firm, advised Perspective Therapeutics (“Perspective”) on its US$87.4 million private placement financing.
Perspective sold 92,009,981 shares of its common stock to institutional accredited investors at US$0.95 per share in a private placement. The price per share matched the closing price of Perspective’s common stock on the NYSE American on March 1, 2024. The private placement closed on March 6, 2024.
Oppenheimer & Co. led the private placement as the lead placement agent. B. Riley Securities and Jones Trading Institutional Services LLC acted as placement agents, while LifeSci Capital served as a co-placement agent.
Perspective Therapeutics is a radiopharmaceutical company developing advanced cancer treatments. They utilise Lead-212, an alpha-emitting isotope, to deliver targeted radiation directly to cancer cells using specialised peptides. Additionally, Perspective is developing complementary imaging diagnostics that employ these same peptides, allowing for personalised treatment plans and improved patient outcomes.
The funds raised from the private placement will be used for various general business needs, including research and development, preclinical and clinical trials, manufacturing, commercialisation, potential acquisitions, and investments in new technologies or businesses.
The Hogan Lovells team was headed by partners Andrew Strong (Houston) and Stephen Nicolai (Philadelphia), accompanied by senior associate Amanda Brown (Philadelphia), along with associates Tyler Glass and Kayvon Paul (both based in Philadelphia).